Osteoporosis characterised by significant reductions of bone mineral density (BMD) and accelerated micro-architectural deterioration, changes which vastly increase skeletal fragility and risk of skeletal fractures. The likelihood of fracture risks become more prominent with the onset of age and have a notably higher prevalence among women, this is thought to be due to reductions of estrogen production occurring during and post-menopause (PM). The onset of menopause is not only associated with increased osteoporosis risk, but also negative changes to lipid status, increased risk for cardiovascular events, vasomotor symptoms and reduced quality of life. The aetiology of these effects is thought to arise from the deficiency of and/or dysregulation by estrogen on target tissues. Hormone Replacement Therapy, although effective against osteoporosis, has proven to be of limited utility in this regard as there is general consensus that it increases cancer risk. Plant derived compounds that emulate the chemical structure and behaviour of estrogen (phytoestrogens) present a compelling potential alternative treatment, as they may adopt the roles of estrogen without incurring equivalent negative side effects. Red clover (RC) is a plant species that is widely grown in Denmark which is known to contain high levels of isoflavones and offers an economically viable source of isoflavones for products targeted towards disorders of estrogen deficiency. The present project exploits novel processing methods which have the potential to open new scientific and commercial prospects for the developing effective treatments for osteopenia.